Bristol-Myers Squibb’s hopes of adding a new indication to the label for S1P modulator Zeposia have been dented after the drug failed a phase 3 trial in Crohn’s disease. A preliminary analysis ...

With Zeposia (to prevent increasing your blood pressure), you will be asked to avoid meals or snacks that are high in ...

Bristol Myers Squibb (NYSE:BMY) said a Phase 3 study for its drug Zeposia in the treatment of moderate-to-severe active Crohn’s disease failed to meet its primary endpoint of clinical remission ...

Bristol-Myers Squibb’s Zeposia (ozanimod) is already tipped for blockbuster sales in its first indication – multiple sclerosis – and new data in ulcerative colitis suggests they could climb ...